Market Overview

Benzinga's Top Downgrades

Related DSW
UPDATE: DSW Shares Rise After Strong Q3 Earnings
Earnings Scheduled For November 25, 2014
Good Time to Buy DSW? (Fox Business)
Related PFE
CNBC'S Catherine Boyle Doesn't Think A Pfizer/AstraZeneca Deal Will Happen Soon
When There's A Pullback On A Bull, Look At These Leading ETFs
Divided Government Won't Halt Street's Run (Fox Business)

Analysts at Sterne Agee downgraded DSW (NYSE: DSW) from Neutral to Underperform. The target price for DSW is set to $23. DSW's shares closed at $27.16 on Friday.

BMO Capital downgraded Pfizer (NYSE: PFE) from Outperform to Market Perform. The target price for Pfizer has been lowered from $34 to $31. Pfizer's shares closed at $30.19 on Friday.

Analysts at Canaccord Genuity downgraded AcelRx Pharmaceuticals (NASDAQ: ACRX) from Buy to Hold. The target price for AcelRx Pharmaceuticals has been lowered from $16.00 to $8.00. AcelRx Pharmaceuticals' shares closed at $10.83 on Friday.

Deutsche Bank downgraded Lear (NYSE: LEA) from Buy to Hold. The target price for Lear has been raised from $100.00 to $103.00. Lear's shares closed at $99.00 on Friday.

Latest Ratings for DSW

DateFirmActionFromTo
Nov 2014CitigroupMaintainsBuy
Nov 2014Credit SuisseMaintainsOutperform
Nov 2014Sterne AgeeUpgradesUnderperformNeutral

View More Analyst Ratings for DSW
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (DSW + ACRX)

Around the Web, We're Loving...

Get Benzinga's Newsletters